NL-201

Neurogene Inc. · Phase 1 active Small molecule

At a glance

Generic name	NL-201
Sponsor	Neurogene Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer (PHASE1)
A Phase Ⅲa Study of Genetically Modified Recombinant Human Interleukin-11 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NL-201 CI brief — competitive landscape report
NL-201 updates RSS · CI watch RSS
Neurogene Inc. portfolio CI